Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Core Insights - Aptose Biosciences Inc. has secured a $10 million loan from Hanmi Pharmaceutical Co. Ltd. to support the development of tuspetinib, an oral kinase inhibitor for acute myeloid leukemia (AML) [1][2] - The loan can be converted into prepayment of milestone obligations or repaid after the completion of a triple drug combination trial with tuspetinib in newly diagnosed AML patients [1] - Aptose and Hanmi are negotiating a new co-development collaboration agreement to provide additional funding for the clinical development of tuspetinib [2] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [3] - The company's lead compound, tuspetinib, has shown efficacy as both a monotherapy and in combination therapy for relapsed or refractory AML, and is being developed as a frontline triplet therapy for newly diagnosed AML [3]